Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Support of legislation to mandate continuous monitoring for patients taking opioids;
Support for policies and legislation to alleviate healthcare worker burnout with the use of medical technology;
Patient safety policy and legislation
Issues related to intellectual property rights and anti-competitive behavior in the medical device supply chain; International Trade Commission
Duration: May 28, 2019
to
present
General Issues: Health Issues , Copyright/Patent/Trademark , Taxation/Internal Revenue Code , Labor Issues/Antitrust/Workplace , Consumer Issues/Safety/Protection , Immigration
Spending: about $1,830,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, U.S. Trade Representative (USTR), White House Office, Commerce - Dept of (DOC), Patent & Trademark Office (PTO), Natl Security Council (NSC), Natl Economic Council (NEC), Intl Trade Administration (ITA), Executive Office of the President (EOP), Office of Natl Drug Control Policy (NDCP), Health & Human Services - Dept of (HHS), Veterans Affairs - Dept of (VA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Catherine Meier
Senior Counsel/Legislative Director, Senator Barbara Boxer; Legislative Assistant/Senior Counsel, Senator Carl Levin
Paul Ordal
Director of Constituent Service, Senator Tom Daschle; Cloakroom Assistant, U.S. Senate Secretary for the Majority; Director of Special Projects/Legislative Assistant, Senator Barbara Boxer; Special Assistant, Senate Environment & Public Works Cmte
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
MASIMO CORPORATION amended a lobbying report for in-house lobbying in Q12024 on April 24
Original Filing: 301577120.xml
Lobbying Issues
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Support of legislation to mandate continuous monitoring for patients taking opioids;
Support for policies and legislation to alleviate healthcare worker burnout with the use of medical technology;
Patient safety policy and legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property rights and anti-competitive behavior in the medical device supply chain; International Trade Commission
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2024
In Q1, MASIMO CORPORATION had in-house lobbyists. The report was filed on April 19.
Original Filing: 301565289.xml
Lobbying Issues
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Support of legislation to mandate continuous monitoring for patients taking opioids;
Support for policies and legislation to alleviate healthcare worker burnout with the use of medical technology;
Patient safety policy and legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property rights and anti-competitive behavior in the medical device supply chain; International Trade Commission
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2023
In Q4, MASIMO CORPORATION had in-house lobbyists. The report was filed on Jan. 22.
Original Filing: 301540520.xml
Lobbying Issues
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Support for adequate coverage and reimbursement in Medicare coverage and reimbursement for medical devices;
Support of legislation to mandate continuous monitoring for patients taking opioids;
Support for policies and legislation to alleviate healthcare worker burnout with the use of medical technology;
Patient safety policy and legislation;
Remote patient monitoring technology Medicare coverage
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and anti-competitive behavior in the medical device supply chain; International Trade Commission
Agencies Lobbied
U.S. Senate U.S. House of Representatives U.S. Trade Representative (USTR) White House Office Commerce - Dept of (DOC) Patent & Trademark Office (PTO) Natl Security Council (NSC) Natl Economic Council (NEC) Intl Trade Administration (ITA)
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2023
In Q3, MASIMO CORPORATION had in-house lobbyists. The report was filed on Oct. 19, 2023.
Original Filing: 301509100.xml
Lobbying Issues
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Support for adequate coverage and reimbursement in Medicare coverage and reimbursement for medical devices;
Support of legislation to mandate continuous monitoring for patients taking opioids;
Support for policies and legislation to alleviate healthcare worker burnout with the use of medical technology;
Patient safety policy and legislation;
Remote patient monitoring technology Medicare coverage;
Support for Medicare coverage and reimbursement pathway for breakthrough technologies (TCET)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and anti-competitive behavior in the medical device supply chain; International Trade Commission
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2023
In Q2, MASIMO CORPORATION had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301491444.xml
Lobbying Issues
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Support for adequate coverage and reimbursement in Medicare coverage and reimbursement for medical devices;
Support of legislation to mandate continuous monitoring for patients taking opioids;
Support for policies and legislation to alleviate healthcare worker burnout with the use of medical technology;
Patient safety policy and legislation;
Remote patient monitoring technology Medicare coverage;
Support for Medicare coverage and reimbursement pathway for breakthrough technologies (TCET)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Support for patent reform legislation and proposals
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Support for R&D tax credit fix
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2023
In Q1, MASIMO CORPORATION had in-house lobbyists. The report was filed on April 19, 2023.
Original Filing: 301459035.xml
Lobbying Issues
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Support for adequate coverage and reimbursement in Medicare coverage and reimbursement for medical devices;
Support of Rep. Kuster/Emmer legislation to mandate continuous monitoring for patients taking opioids;
Support for policies and legislation to alleviate healthcare worker burnout with the use of medical technology;
Patient safety policy and legislation;
Remote patient monitoring technology Medicare coverage;
Support for Medicare coverage and reimbursement pathway for breakthrough technologies (TCET)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Support for patent reform legislation and proposals
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
In Q4, MASIMO CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301441297.xml
Lobbying Issues
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Government Purchasing Organizations (GPOs) and anti-competitive behavior in the medical device supply chain;
Support of Rep. Kuster/Emmer legislation to mandate continuous monitoring for patients taking opioids;
Support for policies and legislation to alleviate healthcare worker burnout with the use of medical technology;
Support for Medicare coverage and reimbursement pathway for breakthrough technologies (TCET);
Patient safety policy and legislation;
Remote patient monitoring technology Medicare coverage and reimbursement and pilot projects.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Office of Natl Drug Control Policy (NDCP)
Lobbying Issues
Support for patent reform legislation and proposals; PTAB/judicial ethics; pro-inventor intellectual property policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives Patent & Trademark Office (PTO)
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Support for R&D tax and SALT cap fix
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Support for the Open App Markets Act (S 2710) and fair competition
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
Type of Issue
Labor Issues/Antitrust/Workplace
3rd Quarter, 2022
In Q3, MASIMO CORPORATION had in-house lobbyists. The report was filed on Oct. 19, 2022.
Original Filing: 301409876.xml
Lobbying Issues
Support for opioid safety consumer education and warning labels and International Overdose Awareness Day;
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Government Purchasing Organizations (GPOs) and anti-competitive behavior in the medical device supply chain;
Support of Rep. Kuster legislation to mandate continuous monitoring for patients taking opioids;
Support for policies and legislation to alleviate healthcare worker burnout with the use of medical technology;
Patient safety policy and legislation;
Remote patient monitoring technology Medicare coverage and reimbursement and pilot projects.
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office Health & Human Services - Dept of (HHS)
Lobbying Issues
Support for patent reform legislation and proposals; PTAB/judicial ethics
Agencies Lobbied
U.S. Senate U.S. House of Representatives Patent & Trademark Office (PTO)
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2022
In Q2, MASIMO CORPORATION had in-house lobbyists. The report was filed on July 19, 2022.
Original Filing: 301386704.xml
Lobbying Issues
Support for the use of medical technology for monitoring of patients taking opioids and the use of technology for withdrawal symptoms, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Support for public education on the dangers of opioid induced respiratory depression and monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Government Purchasing Organizations (GPOs) and anti-competitive behavior in the medical device supply chain;
Remote patient monitoring technology;
Medicare coverage and reimbursement;
Support for regulatory oversight of antitrust violations/anticompetitive behavior;
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office
Lobbying Issues
Dangers of reprocessed medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
Lobbying Issues
Support for patent reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Oppose SALT deduction cap; oppose increases in capital gains tax; support amortization of R&D provision/legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Need for expedited process; more immigrant visas
1st Quarter, 2022
In Q1, MASIMO CORPORATION had in-house lobbyists. The report was filed on April 19, 2022.
Original Filing: 301361729.xml
Lobbying Issues
Support for the use of medical technology for monitoring of patients taking opioids and the use of technology for withdrawal symptoms, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Support for public education on the dangers of opioid induced respiratory depression and monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Government Purchasing Organizations (GPOs) and anti-competitive behavior in the medical device supply chain;
Remote patient monitoring technology;
Medicare coverage and reimbursement;
Support for regulatory oversight of antitrust violations/anticompetitive behavior;
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office
Lobbying Issues
Dangers of reprocessed medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
Lobbying Issues
Support for patent reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Oppose SALT deduction cap; oppose increases in capital gains tax; support amortization of R&D provision/legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Need for expedited process; more immigrant visas
4th Quarter, 2021
In Q4, MASIMO CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301334963.xml
Lobbying Issues
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Government Purchasing Organizations (GPOs) and anti-competitive behavior in the medical device supply chain;
Remote patient monitoring technology;
Medicare coverage and reimbursement
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Dangers of reprocessed medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
Lobbying Issues
Support for patent reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Oppose SALT deduction cap; oppose increases in capital gains tax; support amortization of R&D provision/legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Need for expedited process; more immigrant visas
3rd Quarter, 2021
In Q3, MASIMO CORPORATION had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301309421.xml
Lobbying Issues
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Government Purchasing Organizations (GPOs) and anti-competitive behavior in the medical device supply chain;
Fiscal Year 2022 Labor-Health and Human Services, Education spending bill: Study of continuous monitoring for patients taking opioids;
Remote patient monitoring technology;
Medicare coverage and reimbursement and pilot projects
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Dangers of reprocessed medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
Lobbying Issues
Support for patent reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Oppose SALT deduction cap; oppose increases in capital gains tax.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
In Q2, MASIMO CORPORATION had in-house lobbyists. The report was filed on July 19, 2021.
Original Filing: 301282477.xml
Lobbying Issues
Support for monitoring of patients taking opioids, education for patients, providers, caregivers and the public on the dangers of opioids, and patient safety in general;
Government Purchasing Organizations (GPOs) and anti-competitive behavior in the medical device supply chain;
Fiscal Year 2022 Labor-Health and Human Services, Education spending bill: Study of continuous monitoring for patients taking opioids;
Remote patient monitoring technology;
Medicare coverage and reimbursement and pilot projects
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Office of Natl Drug Control Policy (NDCP) Executive Office of the President (EOP)
Lobbying Issues
Dangers of reprocessed medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
Lobbying Issues
Support for patent reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Oppose SALT deduction cap; oppose increases in capital gains tax.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2021
In Q1, MASIMO CORPORATION had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301265412.xml
Lobbying Issues
Support for continuous monitoring of patients taking opioids and patient safety in general;
Government Purchasing Organizations (GPOs) and anti-competitive behavior in the medical device supply chain;
Fiscal Year 2022 Labor-Health and Human Services, Education spending bill: Study of continuous monitoring for patients taking opioids;
Remote patient monitoring technology;
Medicare coverage and reimbursement and pilot projects
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Veterans Affairs - Dept of (VA)
Lobbying Issues
Dangers of reprocessed medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
Lobbying Issues
Support for patent reform
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2020
In Q4, MASIMO CORPORATION had in-house lobbyists. The report was filed on Jan. 20, 2021.
Original Filing: 301241464.xml
Lobbying Issues
Support for continuous monitoring of patients taking opioids and patient safety in general;
Government Purchasing Organizations (GPOs) and anti-competitive behavior in the medical device supply chain;
Fiscal Year 2021 Labor-Health and Human Services, Education spending bill: Study of continuous monitoring for patients taking opioids;
Remote patient monitoring technology;
Medicare coverage and reimbursement and pilot projects
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Opposition to the Administrations actions banning certain visas
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Dangers of reprocessed medical devices
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
3rd Quarter, 2020
In Q3, MASIMO CORPORATION had in-house lobbyists. The report was filed on Oct. 19, 2020.
Original Filing: 301214074.xml
Lobbying Issues
Support for continuous monitoring of patients taking opioids and patient safety in general;
Government Purchasing Organizations (GPOs) and anti-competitive behavior in the medical device supply chain;
Fiscal Year 2021 Labor-Health and Human Services, Education spending bill: Proposed study of continuous monitoring for patients taking opioids;
COVID19 Response Efforts and patient monitoring;
CARES Act;
Hospital Quality Report Transparency;
Remote patient monitoring technology Medicare coverage and reimbursement and pilot projects
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, MASIMO CORPORATION had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301197007.xml
Lobbying Issues
Support for continuous monitoring of patients taking opioids and patient safety in general;
Government Purchasing Organizations (GPOs) and anti-competitive behavior in the medical device supply chain;
Fiscal Year 2021 Labor-Health and Human Services, Education spending bill: Proposed study of continuous monitoring for patients taking opioids;
COVID19 Response Efforts and patient monitoring;
CARES Act;
Hospital Quality Report Transparency;
Remote patient monitoring technology Medicare coverage and reimbursement and pilot projects
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Immigration - opposition to the President's changes to visa and other immigration policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2020
In Q1, MASIMO CORPORATION had in-house lobbyists. The report was filed on April 16, 2020.
Original Filing: 301168874.xml
Lobbying Issues
Support for continuous monitoring of patients taking opioids and patient safety in general;
S.1227, HR 2376 - Prescription Pricing for the People Act;
S 1895: Lower Health Care Costs Act;
Government Purchasing Organizations (GPOs) and anticompetitive behavior;
Fiscal Year 2021 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development spending bills: Proposed study of continuous monitoring for patients taking opioids;
COVID-19 Response Efforts and patient monitoring;
CARES Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Natl Economic Council (NEC) White House Office Health & Human Services - Dept of (HHS)
4th Quarter, 2019
In Q4, MASIMO CORPORATION had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301127000.xml
Lobbying Issues
Support for continuous monitoring of patients taking opioids and patient safety in general;
S.1227, HR 2376 - Prescription Pricing for the People Act;
S 1895: Lower Health Care Costs Act;
Medical device tax;
Government Purchasing Organizations (GPOs) and anticompetitive behavior;
H.R. 2740: Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development spending bills: Proposed study of continuous monitoring for patients taking opioids.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Natl Economic Council (NEC) White House Office Health & Human Services - Dept of (HHS)
3rd Quarter, 2019
In Q3, MASIMO CORPORATION had in-house lobbyists. The report was filed on Oct. 21, 2019.
Original Filing: 301078043.xml
Lobbying Issues
Support for continuous monitoring of patients taking opioids;
S.1227, HR 2376 - Prescription Pricing for the People Act of 2019;
S 1895: Lower Health Care Costs Act;
Government Purchasing Organizations (GPOs) and anticompetitive behavior;
H.R. 2740: Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development spending bills: Proposed study of continuous monitoring for patients taking opioids.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Health & Human Services - Dept of (HHS)
2nd Quarter, 2019
In Q2, MASIMO CORPORATION had in-house lobbyists. The report was filed on July 22, 2019.
Original Filing: 301055983.xml
Lobbying Issues
Support for continuous monitoring of patients taking opioids.
S.1227, HR 2376 - Prescription Pricing for the People Act of 2019; Government Purchasing Organizations (GPOs) and anticompetitive behavior
Agencies Lobbied
U.S. Senate U.S. House of Representatives White House Office
2nd Quarter, 2019
MASIMO CORPORATION filed a lobbying registration on June 21, 2019 for in-house lobbying efforts, effective May 28, 2019.
Original Filing: 301042298.xml
Issue(s) they said they’d lobby about: Medical technology; patent legislation and law; data sharing; patient safety .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate